CCTV exposes so‑called “universal miracle drug”: is injecting exosomes into the body really safe?

CCTV exposure raises fresh alarms

It has been reported that China Central Television (中央电视台, CCTV) used its March 15 consumer rights programme to expose a wave of clinics and beauty brands marketing exosome (外泌体) products as anti‑aging panaceas and even as treatments for neurological conditions. Huxiu (虎嗅) and other Chinese outlets republished commentary noting that many of these products have unclear compositions, are being sold under unrelated medical‑device registrations, and — reportedly — have caused infections and severe skin reactions in some consumers. Is injecting tiny cell‑derived vesicles into people without full clinical proof really prudent? The short answer from regulators and many scientists is: no.

What exosomes are — and what they are not

Exosomes are a type of small extracellular vesicle produced by cells that can carry proteins, RNA and other molecules; they have attracted real scientific interest as potential biomarkers and drug‑delivery vehicles. But the field remains largely preclinical: no globally approved therapeutic to date is based primarily on exosomes, and laboratory methods vary so much that preparations from different providers can be fundamentally different. Early promising biology does not equate to a safe, standardized injectable product. Researchers warn that where an exosome comes from, what it contains, and where it goes in the body are all open questions requiring rigorous study.

A regulatory gap — and copycat market behaviour

Regulators are taking note. It has been reported that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (国家药品监督管理局药品审评中心) issued a 2025 consultative draft classifying exosome products and proposing that therapeutically active preparations be regulated as drugs, subject to clinical trials. The U.S. Food and Drug Administration (FDA) has already taken enforcement actions against unapproved exosome injections. But in the regulatory gray zone some companies have reportedly “borrowed” approvals for unrelated devices to market exosome‑containing injections — effectively shifting the trial risk to consumers.

What this means for patients and policy

For Western readers unfamiliar with China’s tech and medical markets: this is a local instance of a global pattern — fast commercial hype outpacing science and oversight. Geopolitical tensions and tighter scrutiny of biological technologies have only heightened regulator vigilance worldwide. Until standardized manufacturing, solid human safety data and clear approvals exist, experts say consumers should avoid unapproved exosome injections. Policymakers face a choice: accelerate clear approval pathways and enforcement, or watch a risky do‑it‑first, prove‑later market put patients at hazard.